KAI 1455Alternative Names: KAI-1455
Latest Information Update: 16 Feb 2017
At a glance
- Originator KAI Pharmaceuticals
- Class Anti-ischaemics
- Mechanism of Action Protein kinase stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cardiovascular disorders
Most Recent Events
- 11 May 2007 Phase-I clinical trials in Cardiovascular disorders in USA (IV)